抗体药物偶联物DS-8201a在晚期乳腺癌中的研究进展

抗体药物偶联物(antibody-drug conjugates，ADCs)是一种由抗体、细胞毒药物和偶联链组成的新型抗肿瘤制剂，具有良好的靶向性及抗癌活性。对于既往经过多线治疗失败的人表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）阳性晚期乳腺癌，新一代ADCs制剂DS-8201a在疾病控制率、改善生存等方面具有良好的治疗效果，并对HER-2低表达的晚期乳腺癌患者亦带来生存获益，而药物相关的血液学毒性、间质性肺疾病等安全性问题也引起了广泛关注。本文将就DS-8201a在晚期乳腺癌中的研究进展进行综述。 

Research progress on the use of an antibody–drug conjugate,DS-8201a,in advanced breast cancer

Antibody–drug conjugates (ADCs) represent a new class of antitumor agents composed of an antibody, a cytotoxic drug, and a flexible linker, which together provide highly tumor-specific targeting and potent antitumor activity. For patients with human epidermal growth factor receptor-2 (HER-2)-positive advanced breast cancer who have failed to respond to previous multiline therapies, the next-generation ADC, DS-8201a, delivers a good therapeutic effect as measured by disease control rate and improved survival. It also provides a survival benefit to patients with advanced breast cancer with low HER-2 expression. Drug-related hematological toxicity, interstitial pulmonary disease, and other safety issues have also attracted widespread attention. Here, we reviews the researches addressing the efficacy and safety of DS-8201a in the treatment of advanced breast cancer.